According to Gram Research analysis, a natural compound called Maresin-1 reduced kidney damage in diabetic mice by approximately 30%, measured by decreased harmful protein leakage in urine. The treatment works by activating a protective protein called apolipoprotein D, which suppresses inflammation and oxidative stress in kidney tissue. While these findings are promising, this early-stage research in mice and lab cells has not yet been tested in humans, so it’s not yet available as a treatment.
Researchers discovered that a natural compound called Maresin-1 can help protect kidneys damaged by diabetes. In studies with mice, this compound reduced kidney damage by activating a protective protein called apolipoprotein D. The treatment lowered blood sugar levels and reduced harmful protein leakage in urine by about 30%. This finding could lead to new ways to treat diabetic kidney disease, a serious complication affecting millions of people worldwide. The research suggests that targeting the Maresin-1 pathway might offer hope for patients whose kidneys are damaged by diabetes.
Key Statistics
A 2026 research study found that Maresin-1 treatment reduced harmful protein leakage in diabetic mice’s urine by approximately 30% after 26 weeks of treatment, as measured by the urine albumin-to-creatinine ratio.
In diabetic mice treated with Maresin-1, renal apolipoprotein D expression increased 1.5-fold, and when this protective protein was removed from kidney cells in laboratory studies, Maresin-1’s anti-inflammatory benefits were completely eliminated.
A 2026 study in mice with type 2 diabetic kidney disease showed that Maresin-1 suppressed pro-inflammatory cytokines (IL-1β, TNF-α, and IL-18) while simultaneously increasing protective IL-10 levels in kidney tissue.
The Quick Take
- What they studied: Whether a natural healing compound called Maresin-1 could repair kidney damage caused by diabetes, and how it works inside kidney cells
- Who participated: Laboratory mice with type 2 diabetes created by feeding them a high-fat diet and injecting them with a chemical that damages the pancreas, plus human kidney cells grown in dishes
- Key finding: Maresin-1 treatment reduced harmful protein leakage in diabetic mice’s urine by approximately 30% and lowered blood sugar levels after 26 weeks. The compound worked by activating a protective protein called apolipoprotein D
- What it means for you: This research is early-stage and only tested in mice and lab cells, but it identifies a new potential treatment target for diabetic kidney disease. People with diabetes should continue following their doctor’s current treatment plans while researchers work to develop human treatments based on these findings
The Research Details
Scientists created mice with type 2 diabetes by feeding them high-fat food and injecting them with a chemical that damages insulin-producing cells. They then gave some mice Maresin-1, a natural compound that helps reduce inflammation and repair tissue damage. The researchers measured kidney function, blood sugar levels, and inflammation markers over 26 weeks.
They also studied how Maresin-1 works by examining human kidney cells grown in laboratory dishes. They exposed these cells to high glucose levels (mimicking diabetes) and treated them with Maresin-1. Using advanced protein analysis, they identified which proteins changed when Maresin-1 was active.
To confirm their findings, researchers used genetic techniques to either remove or increase levels of apolipoprotein D (a protective protein) in kidney cells. This showed whether this protein was essential for Maresin-1’s benefits.
This research approach combines animal studies with laboratory cell studies and genetic manipulation. This combination is important because it shows not just that a treatment works, but also reveals the specific mechanism—the biological pathway—that makes it work. Understanding the mechanism helps scientists design better treatments and predict which patients might benefit most.
The study uses multiple complementary methods (animal models, cell cultures, genetic manipulation, and advanced protein analysis) which strengthens confidence in the findings. The research was published in a peer-reviewed journal. However, because this is early-stage research in mice and lab cells, results may not directly translate to humans. The study did not specify the exact number of mice used, which limits assessment of statistical power. Human clinical trials would be needed to confirm these findings are safe and effective in people with diabetes.
What the Results Show
Maresin-1 treatment significantly improved kidney function in diabetic mice. After 26 weeks of treatment, mice receiving Maresin-1 showed lower blood sugar levels compared to untreated diabetic mice. More importantly, the treatment reduced the amount of harmful protein leaking into the urine by approximately 30%, measured by the urine albumin-to-creatinine ratio (UACR)—a key marker of kidney damage.
The compound also reduced scarring and fibrosis in the kidneys, which is a major problem in diabetic kidney disease. Maresin-1 suppressed inflammatory chemicals (IL-1β, TNF-α, and IL-18) that damage kidney tissue while boosting protective chemicals like IL-10 that help repair damage.
The researchers discovered that Maresin-1 works by activating a protective protein called apolipoprotein D (APOD). In diabetic mice, APOD levels increased 1.5-fold when treated with Maresin-1. When scientists removed APOD from kidney cells in the laboratory, Maresin-1 lost its protective effects, proving this protein is essential for the treatment’s benefits.
When researchers artificially increased APOD levels in kidney cells, the anti-inflammatory and antioxidant effects were even stronger than Maresin-1 alone, suggesting that boosting this protective protein could enhance treatment effectiveness. The study also showed that Maresin-1 reduced oxidative stress (harmful reactive oxygen species or ROS) in kidney cells, which is a major driver of kidney damage in diabetes. These secondary findings suggest multiple ways the Maresin-1-APOD pathway protects kidneys.
This research builds on growing evidence that specialized pro-resolving mediators (SPMs) like Maresin-1 can fight inflammation and promote healing. Previous studies showed these compounds help in other inflammatory diseases, but this is among the first to clearly identify apolipoprotein D as a key mechanism in diabetic kidney disease. The 30% reduction in protein leakage is comparable to improvements seen with some current diabetes medications, suggesting Maresin-1 could be a valuable addition to existing treatments.
This study was conducted entirely in mice and laboratory-grown human cells—not in actual patients. Animal models don’t always behave the same way as human bodies. The study did not specify how many mice were used, making it difficult to assess whether the sample size was adequate. The research focused on type 2 diabetes in mice but didn’t test whether results would apply to type 1 diabetes. The long-term safety of Maresin-1 treatment in humans is unknown. Finally, this is basic research identifying a potential target; developing an actual medication would require years of additional testing.
The Bottom Line
This research is too early-stage to recommend Maresin-1 as a treatment. People with diabetes should continue following their doctor’s current treatment plan, which typically includes blood sugar control, blood pressure management, and kidney-protective medications. However, this research identifies a promising new target that pharmaceutical companies may pursue. Patients interested in new diabetes treatments should discuss clinical trial opportunities with their healthcare provider. Confidence level: Low for clinical application (early research), but High for scientific merit and future potential.
This research is most relevant to people with type 2 diabetic kidney disease and their doctors. It’s also important for pharmaceutical researchers developing new treatments. People with diabetes who want to understand emerging therapies should know about this work. However, this is not yet a treatment option—it’s a research finding that may lead to future treatments. People should not seek out Maresin-1 supplements based on this study alone.
If this research leads to human clinical trials, it would typically take 5-10 years before a new medication could be available. Early-phase trials would assess safety, followed by larger trials measuring effectiveness. Even if development proceeds quickly, patients should expect a decade or more before this becomes a standard treatment option.
Frequently Asked Questions
What is Maresin-1 and can I take it for my diabetic kidney disease?
Maresin-1 is a natural compound that helps reduce inflammation and promote tissue healing. While recent research shows it protects kidneys in mice, it is not yet available as a medication for humans. Current treatments prescribed by doctors remain the best option until human clinical trials are completed.
How does Maresin-1 protect kidneys in diabetes?
Maresin-1 activates a protective protein called apolipoprotein D, which reduces inflammation and oxidative stress (harmful cellular damage) in kidney tissue. This protein suppresses inflammatory chemicals that damage kidneys while boosting protective chemicals that promote healing.
When will Maresin-1 be available as a treatment for diabetic kidney disease?
This is early-stage research published in 2026. If development proceeds, human clinical trials would typically take 5-10 years before a medication could become available. Patients should continue current treatments and discuss emerging therapies with their healthcare provider.
Is this research proven to work in humans with diabetes?
No. This research was conducted in mice and laboratory-grown human kidney cells. While results are promising, animal studies don’t always translate to humans. Human clinical trials would be necessary to confirm safety and effectiveness before this could become a standard treatment.
What should I do now if I have diabetic kidney disease?
Continue following your doctor’s current treatment plan, which typically includes blood sugar control, blood pressure management, and kidney-protective medications. Stay informed about emerging treatments by discussing new research with your healthcare provider at regular appointments.
Want to Apply This Research?
- Users with diabetic kidney disease should track their urine albumin-to-creatinine ratio (UACR) as measured by their doctor every 3-6 months, along with blood sugar levels and blood pressure. This allows monitoring of kidney function changes over time and helps assess whether current treatments are working.
- While waiting for new treatments like Maresin-1 to be developed, users can optimize their current kidney health by: tracking daily blood sugar levels, maintaining consistent medication adherence, reducing sodium intake, staying hydrated, and monitoring blood pressure. The app could send reminders for regular kidney function tests and medication refills.
- Create a dashboard showing trends in UACR, eGFR (estimated glomerular filtration rate), blood sugar control, and blood pressure over months and years. Set alerts when values drift outside target ranges. Share this data with healthcare providers at regular appointments to guide treatment adjustments.
This article summarizes early-stage research conducted in mice and laboratory cells. Maresin-1 is not currently approved for human use and is not available as a medication. The findings have not been tested in humans and may not translate directly to human patients. People with diabetic kidney disease should continue following their doctor’s current treatment recommendations and should not attempt to obtain or use Maresin-1 based on this research alone. Always consult with a healthcare provider before making changes to diabetes or kidney disease treatment. This information is for educational purposes only and should not be considered medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.